BMCS Hot Topics: Peptides in Drug Discovery
Synopsis The BMCS Hot Topics online meetings are intended to highlight breaking areas of research in fields of science relevant to drug discovery. They will run as stand-alone half-day virtual events, 2-3 times per year. The programme will be targeted towards researchers working who would like to enhance their understanding of these nascent or developing fields.
Peptides are a key modality for modulating biological pathways with the potential to enable mechanisms inaccessible to traditional small molecules. This meeting will showcase advances in peptide discovery and development, from cyclic and stapled scaffolds to strategies for achieving oral bioavailability. Talks will span discovery and optimisation technologies alongside chemistry strategies for stability, permeability, and delivery, with case studies charting progress from peptide leads to clinical candidates.
Ìý
Registration Registration is open. PleaseÌýÌýto register.
Please note that registrations are for one person per booking.
If you wish to register multiple people from the same organisation, we can offer a sizeable discount. If you are interested, please contact [email protected].
Registration fees: RSC Member: £55.00 Non-Member: £75.00 RSC Student Member: £40.00 Student Non-Member: £50.00
Ìý
Want to become a member? To join the RSC in order to qualify for discounted registration fees at all RSC, please follow thisÌýRSC link.
Ìý
Sponsorship The organising committee are seeking sponsorship from organisations supporting the low registration fees offered to students. If you wish to sponsor, pleaseÌý.
All sponsors will receive the following: – Logo and URL on the meeting website – Logo on the holding slides shown during the breaks at the meeting – Logo included in the delegate handbook – One static slide to be included in the holding slides
Programme
All times quoted are UK Time.
| 13:00 | Opening Remarks |
| Ìý | Session Chair: Marta Brambilla, Johnson & Johnson |
| 13:05 | Pius Baur, Johnson & Johnson Peptides as Biological Therapeutics: Fundamentals & Future Directions |
| 13:45 | Nick Lewis, Bicycle Therapeutics Bicycle®-peptoid hybrids for antimicrobial discovery |
| 14:20 | Poppy Llowarch, AstraZeneca Accelerating peptide hit-to-lead optimisation using affinity-selection mass spectrometry |
| 14:55 | Break |
| Ìý | Session Chair: Hannah Fowler, RSC |
| 15:15 | Christian Heinis, École Polytechnique Fédérale de Lausanne (EPFL) Developing membrane-permeable cyclic peptides |
| 15:50 | Jennifer Johnston, Merck Discovery of Enlicitide: from mRNA display to Phase II |
| 16:25 | Jim Aggen, Circle Pharma Cyclin A/B RxL Inhibitors: A case study for achieving cell permeability and oral bioavailability in macrocyclic peptides |
| 17:00 | Closing Remarks |
| 17:05 | Close of Conference |
Speakers
Pius Baur
Johnson & Johnson
Switzerland
Nick Lewis
Bicycle Therapeutics
UK
Poppy Llowarch
AstraZeneca
UK
Christian Heinis
École Polytechnique Fédérale de Lausanne (EPFL)
Switzerland
Jennifer Johnston
Merck
United States
Jim Aggen
Circle Pharma
United States
Committees
Adrian Hall
UCB
Belgium
Daniel O Donovan
AstraZeneca
UK
Chris Swain
Cambridge MedChem Consulting
UK
Hannah Fowler
RSC
UK
Louise Walport
Imperial College
UK
Marta Brambilla
Johnson & Johnson
Belgium
Event details
Hg3 Conferences Ltd
Hg3 Conferences Ltd
4 Dragon Road Harrogate HG1 5DF